Weili He

2.1k citations

51 papers · 1.4k indexed · h-index 16

Impact in

Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Antifungal resistance and susceptibility
Statistics and Probability top 2%
- Statistical Methods in Clinical Trials

Papers in

Statistics and Probability 30
- Statistical Methods in Clinical Trials 30
- Advanced Causal Inference Techniques 13
Economics and Econometrics 26
- Health Systems, Economic Evaluations, Quality of Life 24
- Pharmaceutical Economics and Policy 7

Co-authors: Judith Feinberg Dianne M. Finkelstein William G. Powderly Peter T. Frame Charles van der Horst Samuel A. Bozzette Stephen A. Spector Hetty Waskin
Journals: Statistics in Biopharmaceutical Research (13 papers)Therapeutic Innovation & Regulatory Science (7 papers)New England Journal of Medicine (3 papers)Clinical Pharmacology & Therapeutics (2 papers)Contemporary Clinical Trials (2 papers)
Partner nations: United States China United Kingdom

In The Last Decade

Weili He

48 papers receiving 1.3k citations

Peers

Countries citing papers authored by Weili He

Since Specialization

Citations

This map shows the geographic impact of Weili He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weili He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weili He more than expected).

Fields of papers citing papers by Weili He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weili He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weili He. The network helps show where Weili He may publish in the future.

Co-authors

The 25 scholars most cited alongside Weili He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weili He Line = papers co-authored together Weili He links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases Pharmacological Research ·Binhua Zou, S. MINI, Weili He, Yan Chen, Lihong Li, Shristi Dhakal, H Yuan, Jeannett Martin, Xiaojuan Li	2025	0
2	Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective Clinical Pharmacology & Therapeutics ·Dragomir J. Pantić, Lei Nie, Shiowjen Lee, Haitao Chu, Jessica E. Kim, Bruce E. Stribling, Weili He, Thomas Jemielita, Susan Gruber, Jacobo D. Varela Traverso, Roy Tamura, 利恵高橋, Yihua Zhao, Yong Chen, Mark van der Laan, Ni Luh Putu Natalia Arik Yudiawati	2025	1
3	Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective Clinical Pharmacology & Therapeutics ·Dragomir J. Pantić, Susan Gruber, Ni Luh Putu Natalia Arik Yudiawati, Haitao Chu, Shiowjen Lee, Haijun Tian, Yan Wang, Weili He, Thomas Jemielita, Jacobo D. Varela Traverso, Roy Tamura, Tian Lu, Yihua Zhao, Yong Chen, Mark van der Laan, Lei Nie	2025	2
4	The Current Landscape of HTA Framework and Key Challenges Statistics in Biopharmaceutical Research ·Min‐Hua Jen, Shahrul Mt‐Isa, Haitao Chu, Ian Bridges, Zhihong Cai, Cornelia Dunger‐Baldauf, Mark Lloyd, Susan Beth O'Brien, Min Ren, Ulrike von Arnim, Weili He	2025	0
5	The hazards of using hazard ratios from proportional hazard models in indirect treatment comparisons Research Synthesis Methods ·Tadakatsu Sugiyama, Jialing Liu, Weili He, Joseph C. Cappelleri, Satrajit Roychoudhury, Yong Chen, Haitao Chu	2025	1
6	Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective Clinical and Translational Science ·Dragomir J. Pantić, Junrui Di, Nadia Daizadeh, Ying Lü, Kaizhi Huang, Yuan Li Shen, H. T. Clifford, Frank W. Rockhold, Herbert Pang, Jing Zhao, Weili He, Andrew Potter, Ni Luh Putu Natalia Arik Yudiawati	2025	10
7	Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction Journal of Advanced Research ·S. MINI, Weili He, Yan Chen, Lihong Li, H Yuan, A.M Rubio, Гайдаш Андрей Иванович, Fengsheng Chen, Shristi Dhakal, Yanhui Tan, Xiaojuan Li	2024	10
8	A new framework to address challenges in quantitative benefit-risk assessment for medical products Contemporary Clinical Trials ·Rahmi Elfitri, Ting Peng, John Scott, Weili He	2020	11
9	On a Stepwise Quantitative Approach for Benefit-Risk Assessment Therapeutic Innovation & Regulatory Science ·Weili He, Yaxuan Sun, Qing Li, William C Verity	2017	2
10	The Case for a Bayesian Approach to Benefit-Risk Assessment: Overview and Future Directions Therapeutic Innovation & Regulatory Science ·TIANLANG LYU, Weili He, P Almagout, Yueqin Zhao, Louder Adriana Vanga-Burgos	2017	6
11	Addressing Challenges and Opportunities of “Less Well-Understood” Adaptive Designs Therapeutic Innovation & Regulatory Science ·Weili He, Paul Gallo, Terrence Woodsome, P Almagout, Jeff Maca, 农学冠, Xiaoyin Fan, Qi Jiang, Cunshan Wang, Min Lin	2016	6
12	DIA’s Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for “Less Well-understood” Adaptive Designs Therapeutic Innovation & Regulatory Science ·Terrence Woodsome, Paul Gallo, Weili He, Lisa A. Kammerman, Kenneth Koury, Jeff Maca, Qi Jiang, Marc K. Walton, Cunshan Wang, صادق صفارزاده, Ritsuko YAMAZOE, P Almagout	2016	7
13	Diary of hot flashes reported upon occurrence Menopause The Journal of The North American Menopause Society ·James A. Simon, Julie Chandler, Keith Gottesdiener, Nicole H. Lazarus, Weili He, Elizabeth Rosenberg, John A. Wagner, Andrew Denker	2014	15
14	Effective Drug Supply for Adaptive Clinical Trials: Recommendations by the DIA Adaptive Design Scientific Working Group Drug Supply Subteam Therapeutic Innovation & Regulatory Science ·Nancy Burnham, إيمان مصطفى درادكة, Weili He, Bryan Baise, Burke Stanton, Nitin Patel, Tom Parke, Jonathan Steinberg	2014	1
15	The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial Clinical Breast Cancer ·Anders Bonde Jensen, Christopher Wynne, Guillermo Ramírez, Weili He, Agatha de Araújo Arruda Anzai Toledo, Yuliya Berd, Hongwei Wang, Zamin Abbas Syed, Antonio Lombardi	2010	105
16	Evaluation of the safety, pharmacokinetics and treatment effects of an α_νβ₃ integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases Asia-Pacific Journal of Clinical Oncology ·Mark Rosenthal, Peter J. Davidson, Frédéric Rolland, Mario Campone, J RAYA, Tae Hyung Han, Anish Mehta, Yuliya Berd, Weili He, Antonio Lombardi	2010	40
17	Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans The Journal of Clinical Pharmacology ·Arthur Bergman, Gail Murphy, Joanne Burke, Jamie J. Zhao, Prof. R. B. Zala, Lida Liu, Kenneth C. Lasseter, Weili He, Thomayant Prueksaritanont, Yue Qiu, Alan Hartford, José M. Vega, John F. Paolini	2004	75
18	A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection New England Journal of Medicine ·Samuel A. Bozzette, Dianne M. Finkelstein, Stephen A. Spector, Peter T. Frame, William G. Powderly, Weili He, Yeung-Muk Kim, Donald E. Craven, Charles van der Horst, Judith Feinberg	1995	239
19	A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection New England Journal of Medicine ·William G. Powderly, Dianne M. Finkelstein, Judith Feinberg, Peter T. Frame, Weili He, Charles van der Horst, Susan L. Koletar, M. Elaine Eyster, John T. Carey, Hetty Waskin, Thomas M. Hooton, Newton E. Hyslop, Stephen A. Spector, Samuel A. Bozzette	1995	228
20	Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. The AIDS Clinical Trials Group. PubMed ·Deborah Cotton, Daniel Finkelstein, Weili He, Judith Feinberg	1993	44

About Weili He

Weili He is a scholar working on Statistics and Probability, Economics and Econometrics, Statistics, Probability and Uncertainty, Complementary and Manual Therapy and Management Science and Operations Research, having authored 51 papers that have together received 1.4k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (30 papers), Health Systems, Economic Evaluations, Quality of Life (24 papers), Advanced Causal Inference Techniques (13 papers), Pharmaceutical Economics and Policy (7 papers), Bone health and treatments (4 papers), Meta-analysis and systematic reviews (4 papers), Biosimilars and Bioanalytical Methods (4 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). The work is most often cited by research in Infectious Diseases (546 citations), Statistics and Probability (234 citations), Epidemiology (657 citations), Virology (52 citations) and Oncology (185 citations). Weili He has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Judith Feinberg, Dianne M. Finkelstein, William G. Powderly, Peter T. Frame, Charles van der Horst, Samuel A. Bozzette, Stephen A. Spector, Hetty Waskin, Roy T. Steigbigel and Donald E. Craven. Their work appears in journals such as Statistics in Biopharmaceutical Research, Therapeutic Innovation & Regulatory Science, New England Journal of Medicine, Clinical Pharmacology & Therapeutics and Contemporary Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact